{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:36:08Z","timestamp":1792272968016,"version":"4.4.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"am","delay-in-days":337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ncl.2024.12.009","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T13:09:25Z","timestamp":1737551365000},"page":"319-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Disease-Modifying Therapies in Parkinson\u2019s Disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Margherita","family":"Fabbri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Christophe","family":"Corvol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ncl.2024.12.009_bib1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00702-019-02115-8","article-title":"Neuroprotection in Parkinson's disease: facts and hopes","volume":"127","author":"Salamon","year":"2020","journal-title":"J\u00a0Neural Transm"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.009_bib2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/mds.28379","article-title":"Seven solutions for neuroprotection in Parkinson's disease","volume":"36","author":"Devos","year":"2021","journal-title":"Mov Disord"},{"issue":"15","key":"10.1016\/j.ncl.2024.12.009_bib3","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.009_bib4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/archneur.1989.00520460028009","article-title":"DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group","volume":"46","year":"1989","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.009_bib5","first-page":"427","article-title":"Parkinson's disease drug therapies in the clinical trial pipeline: 2023 update","volume":"13","author":"McFarthing","year":"2023","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.009_bib6","first-page":"1073","article-title":"Parkinson's disease drug therapies in the clinical trial pipeline: 2022 update","volume":"12","author":"McFarthing","year":"2022","journal-title":"J\u00a0Parkinsons Dis"},{"key":"10.1016\/j.ncl.2024.12.009_bib7","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Prim"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.009_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrneurol.2012.126","article-title":"Late-stage Parkinson disease","volume":"8","author":"Coelho","year":"2012","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.009_bib9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","article-title":"Progress towards therapies for disease modification in Parkinson's disease","volume":"20","author":"Vijiaratnam","year":"2021","journal-title":"Lancet Neurol"},{"issue":"5321","key":"10.1016\/j.ncl.2024.12.009_bib10","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science (New York, NY)"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.009_bib11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/1570159X13666151030104414","article-title":"Counteracting PINK\/Parkin deficiency in the activation of mitophagy: a potential therapeutic intervention for Parkinson's disease","volume":"14","author":"Nardin","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.ncl.2024.12.009_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108085","article-title":"New hopes for disease modification in Parkinson's Disease","volume":"171","author":"Poewe","year":"2020","journal-title":"Neuropharmacology"},{"issue":"10423","key":"10.1016\/j.ncl.2024.12.009_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ncl.2024.12.009_bib14","article-title":"Experimental animal models of prodromal Parkinson's disease","author":"Yamakado","year":"2024","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.009_bib15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1871527322666230223150347","article-title":"Role of animal models in Parkinson's disease (PD): what role they play in preclinical translational research","volume":"23","author":"Srivastava","year":"2024","journal-title":"CNS Neurol Disord - Drug Targets"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.009_bib16","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/mds.27802","article-title":"Update of the MDS research criteria for prodromal Parkinson's disease","volume":"34","author":"Heinzel","year":"2019","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.009_bib17","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamaneurol.2021.1312","article-title":"Emerging neuroimaging biomarkers across disease stage in Parkinson disease: a review","volume":"78","author":"Mitchell","year":"2021","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.009_bib18","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.26332","article-title":"Basic science breaks through: new therapeutic advances in Parkinson's disease","volume":"30","author":"Brundin","year":"2015","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.009_bib19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.27360","article-title":"Disease modification in Parkinson's disease: current approaches, challenges, and future considerations","volume":"33","author":"Lang","year":"2018","journal-title":"Mov Disord"},{"issue":"24","key":"10.1016\/j.ncl.2024.12.009_bib20","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.009_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","article-title":"Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study","volume":"54","author":"Whone","year":"2003","journal-title":"Ann Neurol"},{"issue":"15","key":"10.1016\/j.ncl.2024.12.009_bib22","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group","volume":"284","year":"2000","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.ncl.2024.12.009_bib23","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A\u00a0double-blind, delayed-start trial of rasagiline in Parkinson's disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.009_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/mds.24997","article-title":"Trial designs used to study neuroprotective therapy in Parkinson's disease","volume":"28","author":"Lang","year":"2013","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.009_bib25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.tibs.2018.11.005","article-title":"The cellular environment affects monomeric \u03b1-synuclein structure","volume":"44","author":"Stephens","year":"2019","journal-title":"Trends Biochem Sci"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.009_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/biom10030391","article-title":"Targeting \u03b1-synuclein for PD therapeutics: a pursuit on all fronts","volume":"10","author":"Teil","year":"2020","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.009_bib27","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mdc3.13710","article-title":"\u03b1-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid-A systematic review and meta-analysis","volume":"10","author":"Grossauer","year":"2023","journal-title":"Movement disorders clinical practice"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.009_bib28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/jamaneurol.2014.2704","article-title":"Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease","volume":"72","author":"Kalia","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ncl.2024.12.009_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-323-85555-6.00001-1","article-title":"The shift to a proteinopenia paradigm in neurodegeneration","volume":"193","author":"Ezzat","year":"2023","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.009_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1474-4422(21)00413-0","article-title":"Movement disorders research in 2021: cracking the paradigm","volume":"21","author":"Espay","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2024.12.009_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104587","article-title":"Immunotherapy in Parkinson's disease: current status and future directions","volume":"132","author":"Chatterjee","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.ncl.2024.12.009_bib32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.009_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.009_bib34","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov Disord : official journal of the Movement Disorder Society"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.009_bib35","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.009_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-\u03b1-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.009_bib37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of cinpanemab in early Parkinson's disease","volume":"387","author":"Lang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.009_bib38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson's disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.009_bib39","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/mds.29016","article-title":"A\u00a0randomized first-in-human study with UB-312, a UBITh\u00ae \u03b1-synuclein peptide vaccine","volume":"37","author":"Yu","year":"2022","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.009_bib40","first-page":"1079","article-title":"Safety and tolerability of active immunotherapy targeting \u03b1-synuclein with PD03A in patients with early Parkinson's disease: a randomized, placebo-controlled, phase 1 study","volume":"11","author":"Poewe","year":"2021","journal-title":"J\u00a0Parkinsons Dis"},{"key":"10.1016\/j.ncl.2024.12.009_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105281","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease","volume":"108","author":"Walsh","year":"2023","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.ncl.2024.12.009_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104021","article-title":"Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: a randomised, double-blind, placebo-controlled phase 1a trial","volume":"80","author":"Levin","year":"2022","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.009_bib43","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/mds.29500","article-title":"Genetic testing in Parkinson's disease","volume":"38","author":"Pal","year":"2023","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.009_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cells11081261","article-title":"GBA variants and Parkinson disease: mechanisms and treatments","volume":"11","author":"Smith","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.009_bib45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","article-title":"LRRK2 in Parkinson disease: challenges of clinical trials","volume":"16","author":"Tolosa","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.009_bib46","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1093\/brain\/awaa246","article-title":"Mitochondrial damage-associated inflammation highlights biomarkers in PRKN\/PINK1 parkinsonism","volume":"143","author":"Borsche","year":"2020","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.009_bib47","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/hmg\/ddaa085","article-title":"Glucocerebrosidase deficiency promotes release of \u03b1-synuclein fibrils from cultured neurons","volume":"29","author":"Gegg","year":"2020","journal-title":"Hum Mol Genet"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.009_bib48","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/mds.28195","article-title":"GBA-related Parkinson's disease: dissection of genotype-phenotype correlates in a large Italian cohort","volume":"35","author":"Petrucci","year":"2020","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.009_bib49","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.neuron.2017.12.012","article-title":"Reversible conformational conversion of \u03b1-synuclein into toxic assemblies by glucosylceramide","volume":"97","author":"Zunke","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.ncl.2024.12.009_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105663","article-title":"Glucocerebrosidase-associated Parkinson disease: pathogenic mechanisms and potential drug treatments","volume":"166","author":"Gegg","year":"2022","journal-title":"Neurobiol Dis"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.009_bib51","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","article-title":"Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"22","author":"Giladi","year":"2023","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.009_bib52","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/mds.29346","article-title":"A\u00a0phase 1B trial in GBA1-associated Parkinson's disease of BIA-28-6156, a glucocerebrosidase activator","volume":"38","author":"den Heijer","year":"2023","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.009_bib53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol"},{"issue":"Pt 9","key":"10.1016\/j.ncl.2024.12.009_bib54","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/brain\/awv179","article-title":"Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations","volume":"138","author":"Alcalay","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2024.12.009_bib55","article-title":"An overview of the worldwide distribution of LRRK2 mutations in Parkinson's disease","author":"El Otmani","year":"2024","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.ncl.2024.12.009_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-3-319-49969-7_10","article-title":"LRRK2 and the \"LRRKtosome\" at the crossroads of programmed cell death: clues from RIP kinase relatives","volume":"14","author":"Rideout","year":"2017","journal-title":"Advances in neurobiology"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.009_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/biom12121814","article-title":"Advances in gene therapy techniques to treat LRRK2 gene mutation","volume":"12","author":"Chung","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.009_bib58","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1038\/s41467-019-13413-w","article-title":"LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients","volume":"10","author":"Ysselstein","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.009_bib59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bph.15684","article-title":"Targeting \u03b1-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease","volume":"179","author":"Haque","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.009_bib60","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A\u00a0randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit","volume":"71","author":"Beal","year":"2014","journal-title":"JAMA Neurol"},{"issue":"Pt B","key":"10.1016\/j.ncl.2024.12.009_bib61","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.expneurol.2017.06.017","article-title":"Targeting urate to reduce oxidative stress in Parkinson disease","volume":"298","author":"Crotty","year":"2017","journal-title":"Exp Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.009_bib62","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jama.2021.10207","article-title":"Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial","volume":"326","author":"Schwarzschild","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.009_bib63","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/mds.29450","article-title":"A\u00a0double-blind, randomized, placebo-controlled trial of ursodeoxycholic acid (UDCA) in Parkinson's disease","volume":"38","author":"Payne","year":"2023","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.009_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2020.101890","article-title":"Ferroptosis and its potential role in the physiopathology of Parkinson's Disease","volume":"196","author":"Mahoney-S\u00e1nchez","year":"2021","journal-title":"Prog Neurobiol"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.009_bib65","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/mds.27275","article-title":"Iron as a therapeutic target for Parkinson's disease","volume":"33","author":"Moreau","year":"2018","journal-title":"Mov Disord : official journal of the Movement Disorder Society"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.009_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/ph12030138","article-title":"The efficacy of iron chelators for removing iron from specific brain regions and the pituitary-ironing out the brain","volume":"12","author":"Crichton","year":"2019","journal-title":"Pharmaceuticals"},{"issue":"22","key":"10.1016\/j.ncl.2024.12.009_bib67","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","article-title":"Trial of deferiprone in Parkinson's disease","volume":"387","author":"Devos","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.009_bib68","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12760","article-title":"Impaired brain insulin signalling in Parkinson's disease","volume":"48","author":"Bassil","year":"2022","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.009_bib69","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/mds.29122","article-title":"The impact of type 2 diabetes in Parkinson's disease","volume":"37","author":"Athauda","year":"2022","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.009_bib70","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/mds.29298","article-title":"Type 2 diabetes and Parkinson's disease: a focused review of current concepts","volume":"38","author":"Cullinane","year":"2023","journal-title":"Mov Disord : official journal of the Movement Disorder Society"},{"issue":"1 Suppl","key":"10.1016\/j.ncl.2024.12.009_bib71","first-page":"S38","article-title":"Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic","volume":"10","author":"Foltynie","year":"2014","journal-title":"Alzheimer's Dementia"},{"issue":"10103","key":"10.1016\/j.ncl.2024.12.009_bib72","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.009_bib73","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol"},{"issue":"13","key":"10.1016\/j.ncl.2024.12.009_bib74","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson's disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.009_bib75","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.009_bib76","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/mds.27724","article-title":"Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease","volume":"34","author":"Heiss","year":"2019","journal-title":"Mov Disord"},{"issue":"13","key":"10.1016\/j.ncl.2024.12.009_bib77","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/mds.26426","article-title":"Trophic factors for Parkinson's disease: To live or let die","volume":"30","author":"Olanow","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.009_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1104759","article-title":"Fecal microbiota transplantation in Parkinson's disease-A randomized repeat-dose, placebo-controlled clinical pilot study","volume":"14","author":"DuPont","year":"2023","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.009_bib79","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2284247","article-title":"Efficacy of fecal microbiota transplantation in patients with Parkinson's disease: clinical trial results from a randomized, placebo-controlled design","volume":"15","author":"Cheng","year":"2023","journal-title":"Gut Microb"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.009_bib80","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-071766","article-title":"Safety and feasibility of faecal microbiota transplantation for patients with Parkinson's disease: a protocol for a self-controlled interventional donor-FMT pilot study","volume":"13","author":"Vendrik","year":"2023","journal-title":"BMJ Open"},{"issue":"7 Suppl 1","key":"10.1016\/j.ncl.2024.12.009_bib81","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1212\/WNL.0000000000200787","article-title":"Lifestyle interventions for the prevention of Parkinson disease: a recipe for action","volume":"99","author":"Janssen Daalen","year":"2022","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.009_bib82","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(19)30285-6","article-title":"Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial","volume":"18","author":"van der Kolk","year":"2019","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.009_bib83","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1212\/WNL.0000000000013218","article-title":"Long-term effect of regular physical activity and exercise habits in patients with early Parkinson disease","volume":"98","author":"Tsukita","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.009_bib84","article-title":"Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis","volume":"1","author":"Ernst","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"10.1016\/j.ncl.2024.12.009_bib85","doi-asserted-by":"crossref","first-page":"e2095","DOI":"10.1212\/WNL.0000000000010523","article-title":"Diet pattern and prodromal features of Parkinson disease","volume":"95","author":"Molsberry","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.009_bib86","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2024.12.009_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/mds.29899","article-title":"Advantages and challenges of Platform trials for disease modifying therapies in Parkinson\u2019s disease","author":"Fabbri","year":"2024","journal-title":"Mov Disord"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386192400104X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386192400104X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T14:56:40Z","timestamp":1750777000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073386192400104X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S073386192400104X"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2024.12.009","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-Modifying Therapies in Parkinson\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2024.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}